Shares of Bristol Myers Squibb Co. BMY rose 1.39% to $59.62 Friday, on what proved to be an all-around positive trading ...

Half of all pancreatic cancer patients live less than a year after diagnosis. But researchers say there is potential for ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Bristol Myers Squibb (BMY) concluded the recent trading session at $59.62, signifying a +1.39% move from its prior day's close.

By Karen Roman Biopharmaceutical company ReAlta Life Sciences said it appointed Andrew Miller, Ph.D., to its Board of ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 ---- IND-enabling studies ongoing for PM577 for ...

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and ...